Cybin to Transfer U.S. Stock Exchange Listing to Nasdaq

Core Viewpoint - Cybin Inc. is voluntarily transferring its U.S. stock exchange listing from NYSE American to Nasdaq Global Market, with trading on Nasdaq set to begin on January 5, 2026 [1][2]. Company Overview - Cybin is a clinical-stage pharmaceutical company focused on revolutionizing mental healthcare through innovative treatment options [3][4]. - The company will operate under the new name Helus Pharma and will change its ticker symbol from "CYBN" to "HELP" upon the transfer [2][3]. Business Developments - The transfer to Nasdaq is seen as a significant step in Cybin's evolution into a global pharmaceutical entity [3]. - Cybin is developing CYB003, currently in Phase 3 studies for major depressive disorder, and CYB004, in Phase 2 studies for generalized anxiety disorder, both of which have received regulatory designations [4]. Research Pipeline - The company has a robust pipeline of investigational compounds aimed at addressing unmet needs in mental health treatment [4].